What is Oric Pharmaceuticals, Inc.'s earnings per share (EPS)?

Oric Pharmaceuticals, Inc. (ORIC) reported diluted earnings per share of -$1.47 for fiscal year 2025. This represents a 19.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Oric Pharmaceuticals, Inc. (ORIC) Financials

ORIC

FY2025 annual

Net Income -$129.5M -1.3% YoY

EPS (Diluted) -$1.47 +19.7% YoY

Free Cash Flow -$111.7M +1.9% YoY

Operating Cash Flow -$111.0M +1.5% YoY

Market Cap $1.2B as of Oct 9, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 3.3x on $381.3M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 3, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ORIC SEC filings page.

This page shows Oric Pharmaceuticals, Inc. (ORIC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ORIC FY2025 2026-10-04

ORIC has no reported revenue while R&D dominates spending, leaving operations funded chiefly through capital rather than customers.

In FY2025, the company recorded a net loss of $129M alongside operating cash outflow of $111M, so accounting losses exceeded cash usage and noncash or timing effects mattered. Free cash flow showed a $112M outflow, nearly matching operating cash flow because capital expenditures were only $712K; the business consumes cash in research activities, not physical asset build-out.

R&D was the dominant operating cost: it was 3.3x SG&A in FY2025, making scientific investment more important than commercial overhead in the reported cost structure. With capital expenditures of $712K against operating cash outflow of $111M, nearly all cash use came from running the organization rather than building fixed assets.

Debt-to-equity roughly halved from FY2024 to FY2025 even as total assets increased 49.1%, indicating expansion was not built on heavier leverage. Reported liquidity equaled 42.4 months of latest annual operating outflow, while the current ratio was 14.1x; this describes substantial short-term coverage, not operating self-sufficiency.

Financial Health Signals

Financial health score not available

Oric Pharmaceuticals, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

Oric Pharmaceuticals, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Oric Pharmaceuticals, Inc. reported a net loss of $129.5M while operations used $111.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$45.0M

YoY-16.2%

QoQ-14.4%

Oric Pharmaceuticals, Inc.'s EBITDA was -$45.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 16.2% from the same quarter a year earlier. Against the prior quarter it is down 14.4%.

Net Income

-$41.5M

YoY-14.1%

QoQ-16.0%

Oric Pharmaceuticals, Inc. reported -$41.5M in net income in Q2 2026. This represents a decrease of 14.1% from the same quarter a year earlier. Against the prior quarter it is down 16.0%.

EPS (Diluted)

-$0.38

YoY+19.1%

QoQ-11.8%

Oric Pharmaceuticals, Inc. earned -$0.38 per diluted share (EPS) in Q2 2026. This represents an increase of 19.1% from the same quarter a year earlier. Against the prior quarter it is down 11.8%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$32.0M

YoY-3.4%

QoQ+1.5%

Oric Pharmaceuticals, Inc. recorded an outflow of $32.0M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 3.4% from the same quarter a year earlier. Against the prior quarter it is up 1.5%.

Cash & Debt

$37.5M

YoY-50.6%

QoQ-33.5%

5Y CAGR-26.1%

Oric Pharmaceuticals, Inc. held $37.5M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

104M

YoY+6.7%

QoQ+0.1%

5Y CAGR+21.4%

Oric Pharmaceuticals, Inc. had 104M shares outstanding in Q2 2026. This represents an increase of 6.7% from the same quarter a year earlier. Against the prior quarter it is up 0.1%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-10.9%

YoY+0.3pp

QoQ-2.3pp

Oric Pharmaceuticals, Inc.'s ROE was -10.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 0.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.3 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$36.3M

YoY+18.8%

QoQ+15.5%

Oric Pharmaceuticals, Inc. invested $36.3M in research and development in Q2 2026. This represents an increase of 18.8% from the same quarter a year earlier. Against the prior quarter it is up 15.5%.

Capital Expenditures

$356K

YoY+465.1%

QoQ+17700.0%

5Y CAGR+21.4%

Oric Pharmaceuticals, Inc. invested $356K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 465.1% from the same quarter a year earlier. Against the prior quarter it is up 17700.0%.

Share Buybacks

Not reported for Q2 2026.

ORIC Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ORIC quarterly income statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
R&D Expenses	N/A	$109.8M-3.7%	$114.1M+33.9%	$85.2M+38.1%	$61.7M+8.5%	$56.9M+58.3%	$35.9M+57.2%	$22.8M+20.1%	$19.0M
SG&A Expenses	N/A	$33.2M+15.1%	$28.8M+12.6%	$25.6M+2.1%	$25.1M+14.0%	$22.0M+64.0%	$13.4M+134.4%	$5.7M+71.2%	$3.3M
Operating Income	N/A	-$143.0M-0.1%	-$142.9M-29.0%	-$110.8M-20.7%	-$91.8M-16.4%	-$78.9M-6.3%	-$74.2M-159.7%	-$28.6M-27.7%	-$22.4M
EBITDA	N/A	-$141.8M0.0%	-$141.8M-29.2%	-$109.7M-20.9%	-$90.8M-16.5%	-$78.0M-6.5%	-$73.2M-165.8%	-$27.5M-28.3%	-$21.5M
Income Tax	N/A	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	N/A	-$129.5M-1.3%	-$127.8M-27.0%	-$100.7M-13.0%	-$89.1M-13.2%	-$78.7M-6.8%	-$73.7M-174.2%	-$26.9M-25.8%	-$21.4M
EPS (Basic)	N/A	-$1.47+19.7%	-$1.83+6.6%	-$1.96+12.9%	-$2.25-8.7%	-$2.07	N/A	N/A	N/A
EPS (Diluted)	-$1.32	-$1.47+19.7%	-$1.83+6.6%	-$1.96+12.9%	-$2.25-8.7%	-$2.07	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	88M+25.9%	70M+35.5%	51M+29.7%	40M+4.5%	38M	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$36.3M+18.8%	$31.4M+27.6%	N/A	$28.8M-7.8%	$30.5M+5.6%	$24.6M+12.2%	N/A	$31.2M+39.4%
SG&A Expenses	$9.0M+5.7%	$8.2M+1.3%	N/A	$7.9M+11.0%	$8.5M+20.3%	$8.1M+14.9%	N/A	$7.1M+13.1%
Operating Income	-$45.3M-16.0%	-$39.6M-21.1%	N/A	-$36.7M+4.3%	-$39.1M-8.5%	-$32.7M-12.9%	N/A	-$38.3M-33.6%
EBITDA	-$45.0M-16.2%	-$39.3M-21.4%	N/A	-$36.4M+4.4%	-$38.8M-8.4%	-$32.4M-12.8%	N/A	-$38.0M-33.9%
Net Income	-$41.5M-14.1%	-$35.8M-19.1%	N/A	-$32.6M+5.7%	-$36.4M-13.7%	-$30.0M-20.0%	N/A	-$34.6M-35.7%
EPS (Basic)	-$0.38+19.1%	-$0.34+19.0%	-$0.27+47.1%	-$0.33+32.7%	-$0.47-4.4%	-$0.42-13.5%	-$0.51-2.0%	-$0.49-11.4%
EPS (Diluted)	-$0.38+19.1%	-$0.34+19.0%	-$0.27+47.1%	-$0.33+32.7%	-$0.47-4.4%	-$0.42-13.5%	-$0.51-2.0%	-$0.49-11.4%
Diluted Shares (Avg)	108M+38.3%	105M+48.5%	N/A	99M+40.3%	78M+11.1%	71M+5.5%	N/A	71M+22.9%

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

ORIC Balance Sheet

ORIC quarterly balance sheet

Metric	FY25DEF 14A	FY24DEF 14A	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Total Assets	$408.9M+49.2%	$274.1M+8.8%	$252.0M+2.0%	$247.2M-17.2%	$298.6M-0.1%	$299.0M+217.8%	$94.1M	N/A
Current Assets	$288.5M+10.0%	$262.3M+23.4%	$212.6M+1.0%	$210.5M-12.5%	$240.5M-18.9%	$296.7M+229.7%	$90.0M	N/A
Cash & Equivalents	$45.7M-23.1%	$59.4M+154.0%	$23.4M-65.0%	$66.8M-70.4%	$226.0M+188.1%	$78.4M-12.0%	$89.2M+109.1%	$42.6M
Short-Term Investments	$235.8M+20.0%	$196.6M+6.4%	$184.8M+32.5%	$139.4M+1170.7%	$11.0M-94.9%	$215.2M	$0	$0
Long-Term Investments	$110.8M	$0-100.0%	$26.9M+22.3%	$22.0M-49.4%	$43.4M	$0	$0	$0
Total Liabilities	$24.5M-20.9%	$31.0M+11.1%	$27.9M+12.5%	$24.8M-3.3%	$25.7M+178.3%	$9.2M-95.0%	$184.2M	N/A
Current Liabilities	$20.4M-17.8%	$24.8M+21.4%	$20.5M+32.9%	$15.4M+1.6%	$15.2M+68.3%	$9.0M+68.1%	$5.4M	N/A
Non-Current Liabilities	$4.1M-33.4%	$6.2M-17.2%	$7.5M-21.0%	$9.4M-10.2%	$10.5M+4701.4%	$219K-99.9%	$178.8M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	$10.5M+1650.0%	$600K	N/A	N/A
Total Equity	$384.4M+58.1%	$243.1M+8.5%	$224.1M+0.8%	$222.4M-18.5%	$273.0M-5.8%	$289.8M+421.7%	-$90.1M-39.8%	-$64.4M
Retained Earnings	-$692.2M-23.0%	-$562.8M-29.4%	-$434.9M-30.1%	-$334.2M-36.4%	-$245.1M-47.3%	-$166.4M-79.5%	-$92.7M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$404.7M+16.7%	$436.8M+79.8%	$408.9M+49.2%	$431.2M+42.7%	$346.9M+5.5%	$242.9M-30.8%	$274.1M+8.8%	$302.1M+10.1%
Current Assets	$273.7M-6.0%	$290.2M+37.3%	$288.5M+10.0%	$295.6M+5.8%	$291.1M-1.2%	$211.4M-34.8%	$262.3M+23.4%	$279.4M+20.3%
Cash & Equivalents	$37.5M-50.6%	$56.4M+14.3%	$45.7M-23.1%	$49.7M+12.3%	$75.9M+52.2%	$49.3M-12.5%	$59.4M+154.0%	$44.2M+68.6%
Short-Term Investments	$227.3M+10.0%	$225.5M+46.1%	$235.8M+20.0%	$237.5M+4.1%	$206.6M-12.6%	$154.4M-40.7%	$196.6M+6.4%	$228.1M+13.5%
Long-Term Investments	$122.8M+171.6%	$137.8M+587.6%	$110.8M	$125.9M+1159.3%	$45.2M+104.4%	$20.0M+36.4%	$0-100.0%	$10.0M-65.4%
Total Liabilities	$23.4M+2.5%	$21.2M-8.3%	$24.5M-20.9%	$24.3M-13.5%	$22.9M-13.7%	$23.1M+4.4%	$31.0M+11.1%	$28.1M+4.3%
Current Liabilities	$20.8M+15.0%	$17.8M+0.9%	$20.4M-17.8%	$20.2M-5.0%	$18.1M-7.6%	$17.6M+15.8%	$24.8M+21.4%	$21.2M+12.2%
Non-Current Liabilities	$2.7M-44.5%	$3.4M-37.6%	$4.1M-33.4%	$4.1M-40.0%	$4.8M-30.9%	$5.5M-20.6%	$6.2M-17.2%	$6.8M-14.4%
Total Equity	$381.3M+17.7%	$415.6M+89.1%	$384.4M+58.1%	$406.9M+48.5%	$324.0M+7.1%	$219.7M-33.1%	$243.1M+8.5%	$274.0M+10.7%
Retained Earnings	-$769.5M-22.3%	-$728.0M-22.8%	-$692.2M-23.0%	-$661.7M-25.7%	-$629.1M-27.9%	-$592.8M-28.9%	-$562.8M-29.4%	-$526.5M-29.5%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

ORIC Cash Flow Statement

ORIC quarterly cash flow statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Operating Cash Flow	-$111.6M	-$111.0M+1.5%	-$112.7M-31.5%	-$85.7M-14.0%	-$75.1M-26.2%	-$59.5M-31.5%	-$45.3M-92.4%	-$23.5M-13.8%	-$20.7M
Depreciation & Amortization	N/A	$1.2M+10.2%	$1.1M+7.3%	$1.0M+6.8%	$966K+7.7%	$897K-7.5%	$970K-5.6%	$1.0M+13.8%	$903K
Stock-Based Compensation	N/A	$25.0M+23.9%	$20.2M+32.8%	$15.2M+5.3%	$14.5M+12.5%	$12.9M+143.5%	$5.3M+382.4%	$1.1M+133.3%	$469K
Capital Expenditures	$620K	$712K-40.1%	$1.2M+39.9%	$849K-59.1%	$2.1M+121.3%	$939K+40.8%	$667K-13.2%	$768K+46.3%	$525K
Free Cash Flow	-$112.3M	-$111.7M+1.9%	-$113.8M-31.6%	-$86.5M-12.1%	-$77.2M-27.7%	-$60.5M-31.7%	-$45.9M-89.0%	-$24.3M-14.6%	-$21.2M
Investing Cash Flow	-$99.7M	-$148.0M-768.7%	$22.1M+151.0%	-$43.4M+60.3%	-$109.2M-169.0%	$158.4M+173.4%	-$216.0M-28019.7%	-$768K-51.2%	-$508K
Financing Cash Flow	$172.9M	$245.3M+93.8%	$126.5M+47.7%	$85.7M+239.6%	$25.2M-48.7%	$49.1M-80.4%	$250.5M+253.7%	$70.8M+86.3%	$38.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$31.6M-2.5%	-$32.4M+0.3%	-$22.5M+19.9%	-$25.1M+12.8%	-$30.8M-20.4%	-$32.5M-7.8%	-$28.1M-15.6%	-$28.8M-46.6%
Depreciation & Amortization	$264K-14.8%	$270K-10.6%	$320K+5.3%	$288K+6.7%	$310K+14.0%	$302K+15.7%	$304K+15.6%	$270K+5.1%
Stock-Based Compensation	$7.1M+7.9%	$6.9M+5.2%	N/A	$5.6M+11.4%	$6.6M+31.6%	$6.6M+32.2%	N/A	$5.1M+30.8%
Capital Expenditures	$356K+465.1%	$2K-99.5%	$227K+3.7%	$35K-91.6%	$63K-81.1%	$387K+77.5%	$219K+284.2%	$418K+442.9%
Free Cash Flow	-$32.0M-3.4%	-$32.4M+1.5%	-$22.7M+19.7%	-$25.1M+13.9%	-$30.9M-19.1%	-$32.9M-8.3%	-$28.3M-16.2%	-$29.2M-48.1%
Investing Cash Flow	$11.9M+115.4%	-$18.0M-180.1%	$17.0M-60.2%	-$110.5M-579.1%	-$76.9M-520.8%	$22.4M+136.3%	$42.7M+103.5%	$23.1M+139.9%
Financing Cash Flow	$828K-99.4%	$61.1M+555718.2%	$1.5M+160.9%	$109.5M+86765.9%	$134.3M+16358.6%	$11K-100.0%	$575K+26.9%	$126K+306.5%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ORIC Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ORIC quarterly financial ratios

Metric	FY25DEF 14A	FY24DEF 14A	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Return on Equity	-33.7%+18.9pp	-52.6%-7.7pp	-44.9%-4.9pp	-40.1%-11.2pp	-28.8%-3.4pp	-25.4%	N/A	N/A
Return on Assets	-31.7%+15.0pp	-46.6%-6.7pp	-40.0%-3.9pp	-36.1%-9.7pp	-26.4%-1.7pp	-24.6%+3.9pp	-28.6%	N/A
Current Ratio	14.13+3.6x	10.55+0.2x	10.39-3.3x	13.68-2.2x	15.88-17.1x	32.96+16.1x	16.81	N/A
Debt-to-Equity	0.06-0.1x	0.130.0x	0.120.0x	0.11+0.1x	0.040.0x	0.00	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-10.9%+0.3pp	-8.6%+5.1pp	N/A	-8.0%+4.6pp	-11.2%-0.6pp	-13.7%-6.0pp	N/A	-12.6%-2.3pp
Return on Assets	-10.3%+0.2pp	-8.2%+4.2pp	N/A	-7.6%+3.9pp	-10.5%-0.8pp	-12.4%-5.2pp	N/A	-11.4%-2.2pp
Current Ratio	13.19-2.9x	16.33+4.3x	14.13+3.6x	14.65+1.5x	16.13+1.1x	12.00-9.3x	10.55+0.2x	13.15+0.9x
Debt-to-Equity	0.060.0x	0.05-0.1x	0.06-0.1x	0.060.0x	0.070.0x	0.110.0x	0.130.0x	0.100.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Oric Pharmaceuticals, Inc. ORIC	FY2025	N/A	-$129.5M	N/A	$1.2B	—
Nuvation Bio Inc. NUVB	FY2025	$62.9M	-$204.6M	N/A	$1.7B	57/100
Maze Therapeutics, Inc. MAZE	FY2025	N/A	-$131.1M	N/A	$1.5B	—
Rapport Therapeutics, Inc. RAPP	FY2025	N/A	-$111.5M	N/A	$1.5B	—
Enliven Therapeutics, Inc. ELVN	FY2025	N/A	-$103.7M	N/A	$3.0B	—
180 Life Sciences Corp. ATNF	FY2025	$6.5M	-$450.5M	N/A	$1.1B	12/100

Where Oric Pharmaceuticals, Inc. Ranks

Frequently Asked Questions

Is Oric Pharmaceuticals, Inc. profitable?

No, Oric Pharmaceuticals, Inc. (ORIC) reported a net income of -$129.5M in fiscal year 2025.

What is Oric Pharmaceuticals, Inc.'s EBITDA?

Oric Pharmaceuticals, Inc. (ORIC) had EBITDA of -$141.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Oric Pharmaceuticals, Inc.'s return on equity (ROE)?

Oric Pharmaceuticals, Inc. (ORIC) has a return on equity of -33.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Oric Pharmaceuticals, Inc.'s free cash flow?

Oric Pharmaceuticals, Inc. (ORIC) recorded an outflow of $111.7M in free cash flow during fiscal year 2025. This represents a 1.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Oric Pharmaceuticals, Inc.'s operating cash flow?

Oric Pharmaceuticals, Inc. (ORIC) recorded an outflow of $111.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Oric Pharmaceuticals, Inc.'s total assets?

Oric Pharmaceuticals, Inc. (ORIC) had $408.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Oric Pharmaceuticals, Inc.'s capital expenditures?

Oric Pharmaceuticals, Inc. (ORIC) invested $712K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Oric Pharmaceuticals, Inc. spend on research and development?

Oric Pharmaceuticals, Inc. (ORIC) invested $109.8M in research and development during fiscal year 2025.

How many shares does Oric Pharmaceuticals, Inc. have outstanding?

Oric Pharmaceuticals, Inc. (ORIC) had 100M shares outstanding as of fiscal year 2025.

What is Oric Pharmaceuticals, Inc.'s current ratio?

Oric Pharmaceuticals, Inc. (ORIC) had a current ratio of 14.13 as of fiscal year 2025, which is generally considered healthy.

What is Oric Pharmaceuticals, Inc.'s debt-to-equity ratio?

Oric Pharmaceuticals, Inc. (ORIC) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Oric Pharmaceuticals, Inc.'s return on assets (ROA)?

Oric Pharmaceuticals, Inc. (ORIC) had a return on assets of -31.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Oric Pharmaceuticals, Inc.'s P/E ratio?

Oric Pharmaceuticals, Inc. (ORIC) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $1.2B as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Oric Pharmaceuticals, Inc.'s price-to-sales ratio?

Oric Pharmaceuticals, Inc. (ORIC) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $1.2B as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Oric Pharmaceuticals, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Oric Pharmaceuticals, Inc. (ORIC) held $392.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $111.0M over that year. Dividing the one by the other, the reported balance equals about 42 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Oric Pharmaceuticals, Inc.'s Piotroski F-Score?

Oric Pharmaceuticals, Inc. (ORIC) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Oric Pharmaceuticals, Inc.'s earnings high quality?

Oric Pharmaceuticals, Inc. (ORIC) reported a net loss of $129.5M while operations used $111.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.